Summit Therapeutics Inc. (SMMT)

4,0600 -0,6400 (-13,62%) Alla chiusura: 04:00PM EDT

Summit Therapeutics Inc.

601 Brickell Key Drive
Suite 1000
Miami, FL 33131
United States
650 460 8308
https://www.summittxinc.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 105

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Robert W. Duggan	Co-CEO & Executive Chairman	N/D	N/D	1945
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-CEO, President & Director	657,81k	N/D	1970
Mr. Manmeet Singh Soni	COO, CFO & Director	591,5k	N/D	1978
Prof. Dame Kay Davies DBE, FRS CBE	Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor	N/D	N/D	1951
Mr. Bhaskar Anand	Chief Accounting Officer & Head of Finance	N/D	N/D	1978
Ms. Abby Guzman Murphy	Head of Human Resources	N/D	N/D	N/D
Ms. Divya Chari	Head of Global Clinical Operations	N/D	N/D	1968
Mr. Dave Gancarz	Chief Business & Strategy Officer?	N/D	N/D	N/D
Mr. Will Black	Head of Information Technology?	N/D	N/D	N/D
Dr. Betty Y. Chang Ph.D.	Head of Research, Oncology & Inflammation?	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Governance aziendale

L'ISS Governance QualityScore di Summit Therapeutics Inc. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 5; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.